Nanogen Issued Patent for Addressable Biologic Electrode Arrays
Nanogen, Inc. announced that it was issued U.S. Patent "Addressable Biologic Electrode Array," by the U.S. Patent and Trademark Office. The '936 patent relates to electrode-based array devices and methods of operation in which individual electrodes contained within the array can be selectively addressed or manipulated. The technology enables high-density electrode arrays to be produced and has applications for the hybridization as well as combinatorial synthesis and self-assembly of biological molecules, such as nucleic acids and peptides. The technology also enables the production of smaller and more compact arrays, while at the same time minimizing the utilization of off-chip control circuitry, even for large numbers of electrodes. The technology described in the patent relates to Nanogen's advanced chip designs, which can be used for biological applications and also for nanofabrication applications, such as those described in several other Nanogen patents including the Company's recently issued U.S. Patent No. 6,652,808. With the addition of the '936 patent, Nanogen now has 57 issued patents in the United States.
"Customers using biomedical diagnostic applications -- and ultimately the patients they serve -- will require increasingly sophisticated capabilities at reasonable cost," said Howard Birndorf, Nanogen chairman and chief executive officer. "Application of the technology described in this patent allows for continually increasing array densities and capabilities, which simultaneously would reduce both array cost and instrument size."
"One of the challenges in producing biologic arrays of increasing density is the integration of electronic control circuitry with each electrode on the array. The new patent describes a semiconductor-based switching technology that helps solve these scaling issues," said Dr. Michael J. Heller, co-founder of Nanogen, and currently a professor in the Departments of Bioengineering and Electrical and Computer Engineering at the University of California, San Diego.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.